Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ITI regimens with Myozyme in previously treated Pompe disease
2015-000583-34Phase 4
- Sponsor
- Sanofi
- Start
- Apr 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of alglucosidase alfa, rituximab, cyclophosphamide and methotrexate in Pompe disease (2 arms), sponsored by Sanofi. Primary endpoint: Efficacy of immune tolerance induction by anti-rhGAA antibody response.
02
Drugs
alglucosidase alfarituximabcyclophosphamidemethotrexate
03
Conditions
Pompe disease
Beyond the preview
Go deeper on 2015-000583-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000583-34.